PMOS (Formerly PCOS): What It Is, Every Treatment Option, and What I Tell My Patients

If you have been diagnosed with polycystic ovary syndrome, your condition now has a new name. In May 2026, an international consortium of 56 patient and professional organizations published a consensus in The Lancet renaming PCOS to polyendocrine metabolic ovarian syndrome, or PMOS.¹ The diagnosis has not changed. The diagnostic criteria have not changed. Your treatment plan has not changed. What changed is that the medical community finally acknowledged what patients and clinicians have known for years: the old name was wrong, and it was causing real harm.

I see PMOS constantly in my practice. It is the most common endocrine disorder in women of reproductive age. The 2023 international guideline puts prevalence at 10 to 13 percent, and the renaming consortium describes it as affecting roughly one in eight women worldwide.^1,3 Many of them waited years for a diagnosis because a previous provider looked at an ultrasound, saw no "cysts," and dismissed the possibility. The new name exists to prevent exactly that mistake. There are no cysts. There never were. What ultrasound shows are arrested follicles, and their presence or absence is only one of three diagnostic criteria, not a requirement.

Why the name changed

The term "polycystic ovary syndrome" implied that the condition was defined by pathological ovarian cysts. It was not. It never has been. The so-called cysts are small antral follicles that stopped developing. They are not harmful growths. They are a morphological finding that may or may not be present in a woman who has the condition.¹

Worse, the old name anchored everything to the ovary, which obscured the systemic nature of the disorder. PMOS involves the endocrine system broadly: insulin resistance, androgen excess, disrupted gonadotropin signaling, metabolic dysfunction, and downstream effects on cardiovascular health, mental health, liver, and skin. Calling it an ovary problem was like calling type 2 diabetes a pancreas problem. Technically true. Practically misleading.

The renaming process involved surveys of over 22,000 patients and health professionals across all world regions, followed by modified Delphi consensus workshops. The three prioritized terms were polyendocrine (multiple hormone systems involved), metabolic (insulin resistance and metabolic dysfunction are central), and ovarian (the ovary is involved, just not the whole story). Both the Endocrine Society and the American Society for Reproductive Medicine have endorsed the change.¹ A three-year transition period began in May 2026, with full adoption expected in the 2028 International Classification of Diseases update.

What is PCOS — and why is it now called PMOS?

PMOS is a hormonal and metabolic disorder. At its foundation is a feedback loop between insulin resistance and androgen excess. Elevated insulin stimulates the ovaries to produce more androgens (testosterone, androstenedione, DHEA-S). Those androgens disrupt follicular development and ovulation. The disrupted ovulation leads to irregular or absent periods. The irregular periods lead to inadequate progesterone exposure, which raises the long-term risk of endometrial hyperplasia and endometrial cancer.²

But the effects are not confined to the reproductive system. Insulin resistance drives weight gain, particularly in the midsection. It raises triglycerides and lowers HDL cholesterol. It increases the risk of impaired glucose tolerance and type 2 diabetes, and it raises cardiovascular risk. It is associated with higher rates of obstructive sleep apnea, non-alcoholic fatty liver disease, and depression.^2,3

PMOS is not one thing. It is a syndrome, meaning a cluster of features that travel together. Not every patient has every feature, and the relative prominence of insulin resistance versus androgen excess versus ovulatory dysfunction varies from person to person. This heterogeneity is one reason the condition gets missed so often.

Symptoms

What are the first signs of PMOS?

The earliest signal is usually a menstrual pattern that never settles into regularity. Most of my patients trace it back to adolescence — cycles that stayed unpredictable years after their first period while their friends' periods normalized. The second common early sign is acne that clusters along the jawline and lower face rather than the forehead, which is where typical teenage breakouts concentrate. A third early marker patients often miss is slow weight gain around the midsection that resists diet and exercise, what patients call "PCOS belly." That central weight pattern reflects insulin resistance depositing fat viscerally rather than subcutaneously.

PMOS belly and body shape

The abdominal fat pattern in PMOS is not cosmetic. It is visceral adiposity driven by insulin resistance, and it carries disproportionate metabolic risk. Patients describe a PCOS stomach or PCOS belly shape — weight concentrated between the ribs and hips while arms and legs stay relatively lean. Some patients also notice facial roundness they call PCOS moon face, though true Cushingoid facies should prompt a cortisol workup to rule out Cushing syndrome. Excess facial hair, including chin hair and in more pronounced cases what patients call a PCOS beard, is hirsutism from androgen excess. It is not a cosmetic quirk, and it responds to hormonal treatment.

Types of PMOS

The 2023 guideline does not formally endorse phenotypic subtypes, but clinically I find it useful to think in terms of the dominant driver. Some patients present with insulin resistance as the primary feature: weight gain, acanthosis nigricans, prediabetes, with relatively mild androgen symptoms. Others present with pronounced hyperandrogenism (severe acne, hirsutism, hair loss) but near-normal metabolic markers. A third group has primarily ovulatory dysfunction with subtle findings in the other two domains. These are not rigid categories. Most patients sit on a spectrum, and the dominant feature can shift over time, particularly with weight change or aging. What matters for treatment is identifying which axis is driving the most harm right now.

What I emphasize to patients is that weight is normal or low in a substantial minority of women with PMOS.² The condition is not exclusive to women with obesity. A lean patient with irregular periods, cystic acne along the jawline, and elevated free testosterone has PMOS just as much as a patient with a BMI of 38. The diagnostic criteria do not include a weight threshold.

How I diagnose it

The 2023 international evidence-based guidelines, which remain the current standard through the PMOS transition, use the Rotterdam criteria. A diagnosis requires at least two of the following three:³

1. Ovulatory dysfunction. Irregular menstrual cycles, defined as cycles shorter than 21 days or longer than 35 days (from three years after menarche through perimenopause), or absent periods.

2. Hyperandrogenism. Either clinical (hirsutism scored by the modified Ferriman-Gallwey scale, persistent acne, androgenic alopecia) or biochemical (elevated total testosterone, free testosterone, or DHEA-S on lab testing).

3. Polycystic ovarian morphology. On transvaginal ultrasound, 20 or more follicles (2 to 9 mm diameter) in either ovary, or an ovarian volume of 10 mL or greater. In adolescents, ultrasound is not required and should not be used as a sole diagnostic criterion because multi-follicular ovaries are normal in that age group.³

PMOS is a diagnosis of exclusion. Before I make it, I rule out thyroid disease, hyperprolactinemia, non-classical congenital adrenal hyperplasia (via a 17-hydroxyprogesterone level), and Cushing syndrome. These conditions can all mimic PMOS, and missing them changes the treatment entirely.

PMOS vs endometriosis

These are distinct conditions that can coexist. PMOS is an endocrine disorder centered on insulin resistance and androgen excess. Endometriosis is the growth of endometrial-like tissue outside the uterus, driven by estrogen and causing pain, inflammation, and adhesions. The overlap in symptoms (pelvic pain, heavy periods, difficulty conceiving) means patients sometimes get one diagnosis when they have both, or get neither when each condition is assumed to explain the other's symptoms. If a patient with PMOS has pain that worsens cyclically, pain with intercourse, or pain with bowel movements, I evaluate for endometriosis separately.

PCOD vs PMOS

PCOD — polycystic ovarian disease — is an older term used primarily in South Asian medical practice. It is not a separate diagnosis. Clinically, PCOD refers to the same condition now called PMOS (formerly PCOS). The Rotterdam diagnostic criteria apply regardless of which name was used at the time of diagnosis. If you were diagnosed with PCOD, your condition, your treatment, and your monitoring should be the same as for PMOS.

Treatment

PMOS treatment is not one-size-fits-all. The right approach depends on three questions: what are the dominant symptoms, is pregnancy desired now, and how significant is the metabolic component? I walk through every tool I use, organized by clinical goal.

Lifestyle modification comes first

This is not a throwaway line. Structured lifestyle intervention is the first-line recommendation in every major PMOS guideline for a reason: modest weight loss of 5 to 10 percent of body weight in women with elevated BMI can restore ovulatory cycles, reduce androgens, improve insulin sensitivity, and lower cardiovascular risk factors.³ The 2023 guidelines specifically recommend against any single named diet. A Mediterranean-style eating pattern has the most evidence, but what matters more than the label is caloric balance and sustainability.

Exercise recommendations are 150 minutes per week of moderate-intensity activity plus resistance training two to three times per week. Resistance training deserves emphasis because it improves insulin sensitivity through a pathway that does not require weight loss, and it builds metabolically active tissue that improves glucose handling at rest.

Medications for insulin resistance

In my practice, metformin remains the default for patients with significant insulin resistance or prediabetes because it has the deepest evidence base and the longest track record. When patients ask about supplements for PMOS — or search "vitamins for PCOS" — myo-inositol is my first conversation for patients who want to start with something available without a prescription, who cannot tolerate metformin's gastrointestinal effects, or who are prioritizing fertility (the oocyte-quality data are specific to inositol, not metformin). I am transparent with patients about what the guideline actually says: metformin outperforms inositol, and the guideline characterizes inositol's clinical benefit as limited.³ Inositol is not a superior alternative to metformin. It is a better-tolerated one with weaker evidence, and for some patients that trade is worth making. Berberine I discuss when a patient specifically asks about it. The network meta-analysis data are favorable, but the studies are smaller and shorter than the metformin literature.⁵

Medications for androgen symptoms

Combined oral contraceptives are the first-line treatment for menstrual irregularity, acne, and hirsutism in women who do not want to conceive. They suppress ovarian androgen production, raise sex hormone-binding globulin (which binds free testosterone), and provide regular withdrawal bleeds that protect the endometrium from hyperplasia.³

Spironolactone is an androgen receptor blocker that I add when acne or hirsutism does not respond adequately to contraceptives alone. Typical doses are 50 to 100 mg daily, sometimes up to 200 mg. It is teratogenic, so reliable contraception must be in place before I prescribe it. Spironolactone takes three to six months to show full effect on hair growth. I tell patients not to judge it before the six-month mark.

For acne specifically, topical retinoids and benzoyl peroxide work on the skin surface while oral medications address the hormonal driver. Persistent hormonal acne along the jawline and chin that does not respond to topical treatment is one of the most common presentations that leads to a PMOS diagnosis in my office.

For hair loss, the pattern in PMOS is typically thinning at the crown and widening of the part, distinct from the patchy loss of alopecia areata. Treatment is slow. Minoxidil (topical, 5 percent) plus the hormonal management described above is the standard approach. Hair growth cycles are long, so visible improvement takes six to twelve months.

Medications for fertility

When pregnancy is the goal, the approach shifts. Combined oral contraceptives are stopped. Ovulation induction becomes the priority.

Letrozole is now the first-line ovulation induction agent for PMOS, replacing clomiphene, based on the 2023 guideline and on the NICHD trial of 750 women showing higher ovulation and live-birth rates with letrozole.^3,7 It works by blocking estrogen synthesis, which causes the pituitary to release more FSH, which stimulates follicular development.

Clomiphene remains an option, particularly where letrozole is not available or not tolerated. It is an estrogen receptor modulator that triggers FSH release through a different mechanism.

Metformin is often continued or added alongside ovulation induction, particularly in women with insulin resistance, as it may improve ovulation rates as an adjunct.³

For women who do not respond to oral ovulation induction, the next steps are gonadotropin injections and, if needed, in vitro fertilization. These are managed by reproductive endocrinology specialists, and I refer early when first-line approaches are not working.

GLP-1 medications and PMOS

GLP-1 receptor agonists — Ozempic and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide) — are not FDA-approved for PMOS. Their approved indications are type 2 diabetes and chronic weight management. But for women whose PMOS is significantly driven by obesity and insulin resistance, the off-label use of GLP-1 medications is growing, and the early data are promising.

An early proof-of-concept analysis from the RESTORE trial at the University of Colorado Anschutz, published in Fertility and Sterility in June 2026, found improved reproductive measures in participants who achieved at least 10 percent weight loss on injectable semaglutide.⁸ The weight loss and insulin sensitization can restore ovulation in women who have been anovulatory for years.

I have written a separate comprehensive guide to GLP-1 medications, including their interaction with PMOS, fertility, contraception, and pregnancy: GLP-1 Medications: What These Drugs Actually Do, Who They Help, and What I Tell My Patients.

The critical safety warning I repeat: if you start a GLP-1 medication and are not using reliable contraception, start immediately. Restored ovulation can happen within weeks, before you notice any change in your cycle. Tirzepatide may also reduce absorption of oral contraceptive pills due to slowed gastric emptying. Non-oral contraception (IUD, implant, ring) is the safer choice during titration.

The PMOS diet question

Patients ask me about "the PCOS diet" constantly. There is no single PCOS diet validated in clinical trials. What the evidence supports are dietary principles that address the metabolic core of the condition:³

Reduce glycemic load. Swap refined carbohydrates for whole grains, legumes, and vegetables. The goal is to avoid the insulin spikes that drive androgen production. This does not mean zero carbohydrates. It means choosing carbohydrates that release glucose slowly.

Prioritize protein. Protein at every meal stabilizes blood sugar, supports satiety, and preserves lean mass during any weight loss. Eggs, fish, poultry, legumes, Greek yogurt, and nuts are practical sources.

Include anti-inflammatory fats. Omega-3 fatty acids from fish, olive oil, avocado, and nuts may help reduce the chronic low-grade inflammation that characterizes PMOS.

Fiber. Soluble fiber slows glucose absorption and feeds the gut microbiome, which emerging research links to hormonal metabolism in PMOS. Oats, lentils, flaxseed, and vegetables are high-yield sources.

A Mediterranean-style pattern hits all of these targets without requiring rigid rules. But the best diet for PMOS is one the patient will actually follow for years. I do not prescribe elimination diets, and I do not recommend extreme caloric restriction, which can worsen hormonal dysregulation and trigger disordered eating in a population already at elevated risk for it.

Long-term health risks

The cardiovascular risk deserves specific attention. A 2024 systematic review and meta-analysis informing the international guidelines found elevated clinical cardiovascular disease in women with PMOS, not just elevated risk factors.⁹ This is not a distant theoretical concern. It is why I order lipid panels on my PMOS patients, even the 22-year-olds.

PMOS in adolescents

Diagnosing PMOS in teenagers is harder and requires extra caution. Irregular periods are normal in the first two to three years after menarche. Multi-follicular ovaries are a normal finding in adolescents and should not be used as a diagnostic criterion. The 2023 guidelines explicitly recommend against using ultrasound alone for diagnosis in this age group.³

In an adolescent, I consider PMOS when menstrual irregularity persists beyond three years after menarche, combined with clinical or biochemical hyperandrogenism. I am cautious about labeling, because a premature diagnosis carries psychological weight. But I am equally cautious about dismissing persistent symptoms, because early intervention with lifestyle and, when appropriate, metformin or oral contraceptives can alter the metabolic trajectory before it becomes entrenched.

Is PMOS genetic?

There is a strong heritable component. Twin studies estimate that roughly 70 percent of the variance in PMOS risk is heritable, with the largest study putting the monozygotic-twin concordance at more than double that of dizygotic twins. If your mother or sister has it, your own risk is substantially elevated. The inherited component is a predisposition, not a certainty. The genes involved relate primarily to insulin signaling, androgen metabolism, and gonadotropin regulation, and whether they express clinically depends on factors like prenatal androgen exposure, weight trajectory, and diet. This is why two sisters can carry the same risk variants while only one develops symptoms.¹³

Is PMOS curable?

No. There is no cure. I say this directly because patients are owed honesty, not false hope from someone selling a "PCOS cure" protocol. PMOS is a chronic endocrine condition with a genetic basis. It can be managed effectively — symptoms controlled, fertility restored, long-term risks reduced — but the underlying predisposition does not disappear. What treatment changes is the trajectory: symptoms brought under control, fertility restored when it is the goal, metabolic risk lowered. The aim is durable remission of symptoms, not erasure of the diagnosis.

Is PMOS an autoimmune disease?

No, though I understand why the question comes up. Chronic low-grade inflammation is a feature of PMOS, and some autoimmune conditions, Hashimoto thyroiditis in particular, co-occur at higher rates. But PMOS is an endocrine and metabolic disorder, not an autoimmune one. The immune system is not attacking the ovaries. The confusion arises because inflammation, insulin resistance, and hormonal disruption all interact, and the symptom burden can feel similar to autoimmune conditions. Getting the category right matters because it determines treatment: immunosuppression does not help PMOS. Insulin sensitization does.

What I tell patients

This is a chronic condition, not a short-term problem. There is no cure for PMOS. There is management that, done well, can control symptoms, protect fertility, and substantially reduce long-term health risks. The patients who do best are the ones who understand that treatment is ongoing, not episodic.

The name change matters, but not in the way you might think. Your diagnosis has not changed. Your labs have not changed. What has changed is that the medical establishment is no longer describing your condition with a term that was inaccurate from the start. If you ever had a provider dismiss your symptoms because your ultrasound looked "normal," the new name is the field's acknowledgment that that should not have happened.

Insulin resistance is the engine. If there is one concept to internalize, it is this: managing insulin resistance through diet, exercise, and medication when needed is the single most impactful thing you can do for every downstream symptom, from acne to irregular periods to difficulty conceiving.

Weight is a factor, not a sentence. Not every woman with PMOS is overweight. Not every overweight woman with PMOS needs to lose weight to improve. But for those where weight is a driver, even modest loss produces outsized hormonal improvement.

Your mental health counts. The 2023 guidelines formally recommend depression and anxiety screening for every patient with PMOS. If you are struggling, that is part of the condition, not separate from it. Ask for help.

Demand your labs. A diagnosis of PMOS without a metabolic workup is an incomplete diagnosis. You should know your fasting insulin, your glucose, your HbA1c, and your lipids. If your provider has not ordered them, ask.

Frequently asked questions

Is PMOS reversible? Can it be cured?

There is no permanent cure, but the symptoms are highly reversible with treatment. When patients ask how to reverse PMOS, my answer is that weight loss, insulin sensitization, and hormonal management can restore regular cycles, resolve acne, and normalize androgens. The underlying genetic predisposition remains, which is why "how to cure PCOS permanently" has no honest yes. After menopause, when ovarian androgen production declines, symptoms often improve on their own.

Can you get pregnant with PMOS?

Yes. PMOS is the most common cause of ovulation-related infertility, but it is also one of the most treatable. Many women with PMOS conceive naturally, and many more conceive with ovulation induction using letrozole. Having PMOS does not mean you are infertile. It means ovulation is unpredictable, and restoring it is usually achievable. If you are trying to conceive and have not succeeded after six months, I recommend an evaluation rather than waiting a full year.

How do doctors test for PMOS?

There is no single test. I diagnose PMOS by applying the Rotterdam criteria: you need at least two of three features (irregular ovulation, clinical or biochemical androgen excess, and polycystic ovarian morphology on ultrasound). The workup includes blood tests for testosterone, DHEA-S, 17-hydroxyprogesterone, TSH, prolactin, glucose, and insulin, plus a pelvic ultrasound in adults. It is a diagnosis of exclusion, so I rule out thyroid disease, adrenal conditions, and Cushing syndrome first.

Can men have PMOS?

No. PMOS involves the ovaries, so men cannot have it. But the genetics matter for families: fathers, brothers, and sons of women with PMOS show higher rates of insulin resistance, early hair loss, and prediabetes. This points to a shared genetic-metabolic phenotype that expresses differently depending on sex. If a woman in your family has PMOS, the men may carry related metabolic risk worth monitoring.

Is PMOS a disability?

PMOS is not listed as a standalone disability under the Americans with Disabilities Act. However, its complications, including chronic fatigue, severe depression, and infertility, can qualify a person for reasonable workplace accommodations under the ADA, and the Social Security Administration may consider endocrine disorders that cause significant functional impairment. Eligibility is assessed case by case based on how the condition affects daily function, not on the diagnosis alone.

Does PMOS cause painful or heavy periods?

It can. The irregular, infrequent ovulation of PMOS often leads to a thickened uterine lining, and when a period finally comes it can be heavy and prolonged. Some patients also experience significant cramping. That said, severe cyclical pain or pain with intercourse should prompt evaluation for endometriosis, which is a separate condition that can coexist with PMOS. Persistent heavy bleeding always warrants assessment to protect the endometrium.

Does PMOS make you tired?

Fatigue is common, and it usually traces back to the metabolic core of the condition. Insulin resistance causes blood sugar swings that leave patients drained. Poor sleep, higher rates of obstructive sleep apnea, iron deficiency from heavy periods, and the burden of depression and anxiety all compound it. Fatigue in PMOS is real and physiological, not a personal failing, and addressing the insulin resistance often improves it.

How can I stop PMOS facial hair growth naturally?

Truly natural approaches are limited. Managing insulin resistance through diet and exercise can slow new growth over months, and spearmint tea has modest anti-androgen evidence. But established hirsutism responds far better to medical treatment: combined oral contraceptives lower androgens, spironolactone blocks them at the follicle, and mechanical methods like laser hair removal address existing hair. Hair growth cycles are long, so any approach takes three to six months to show results.

Will insurance cover Ozempic for PMOS?

Usually not for PMOS specifically, because GLP-1 medications are not FDA-approved for that indication. Coverage typically requires an approved diagnosis such as type 2 diabetes or, for the weight-management formulations, meeting BMI criteria. Some patients with PMOS and significant insulin resistance or obesity qualify on those grounds. I work through the specific coverage pathway with each patient rather than assuming a blanket answer.

Can PMOS develop later in life?

The underlying tendency is present from early reproductive years, but symptoms can surface or worsen later, often triggered by weight gain, stress, or coming off hormonal birth control. What patients call "post-pill PCOS" is usually the condition becoming visible once the pill's hormonal masking is removed, rather than a brand-new disorder. A genuinely new onset of these symptoms in your thirties or forties warrants a workup to rule out other causes.

References

1. Teede HJ, Bahri Khomami M, Morman R, et al; Global Name Change Consortium. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339. doi:10.1016/S0140-6736(26)00717-8. Endorsed by the Endocrine Society and the American Society for Reproductive Medicine.
2. Shukla A, Rasquin LI, Anastasopoulou C. Polyendocrine Metabolic Ovarian Syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; updated 2026. PMID 29083730
3. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. doi:10.1210/clinem/dgad463. PMID 37580314
4. Systematic review and meta-analysis of inositol for PCOS informing the 2023 international evidence-based guideline update. J Clin Endocrinol Metab. 2024. PMC11099481
5. Zhao H, Xing C, Zhang J, He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021;18(1):171. PMC8371888
6. Mishra N, Verma R, Jadaun P. Study on the effect of berberine, myoinositol, and metformin in women with polycystic ovary syndrome: a prospective randomised study. Cureus. 2022;14(1):e21781. doi:10.7759/cureus.21781. PMID 35251851
7. Legro RS, Brzyski RG, Diamond MP, et al; NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119-129. doi:10.1056/NEJMoa1313517. PMID 25006718
8. Cree MG, Garcia-Reyes Y, Shapiro A, et al. Weight loss associated with semaglutide use is linked to improved reproductive measures in PMOS: a proof-of-concept analysis. Fertil Steril. 2026. University of Colorado Anschutz Medical Campus, RESTORE trial.
9. Tay CT, Mousa A, Vyas A, et al. 2023 international evidence-based polycystic ovary syndrome guideline update: insights from a systematic review and meta-analysis on elevated clinical cardiovascular disease in polycystic ovary syndrome. J Am Heart Assoc. 2024;13:e033572.
10. Endometrial cancer risk in PCOS/PMOS: the ESHRE/ASRM Amsterdam consensus reports a 2.7-fold increased risk (95% CI 1.0-7.3); a meta-analysis summarized in Cleveland Clinic Journal of Medicine (2026;93(3):176) found up to a 4-fold increase in premenopausal women. ccjm.org
11. Depression, anxiety, and risk of metabolic syndrome in women with polycystic ovary syndrome: a longitudinal study. J Clin Endocrinol Metab. 2024;110(3):e750. academic.oup.com
12. Merck Manual Professional Edition. Polyendocrine Metabolic Ovarian Syndrome (PMOS). Full review June 2026 by JoAnn V. Pinkerton, MD. merckmanuals.com
13. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100-2104. PMID 16219714
14. Cleveland Clinic. PMOS (Polyendocrine Metabolic Ovarian Syndrome): Symptoms and Treatment. Updated 2026. clevelandclinic.org
15. Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): current and future trends. J Clin Invest. 2026. jci.org

This article is educational and does not constitute medical advice or establish a physician-patient relationship. PMOS management requires individualized care from a qualified clinician. Consult your own physician before starting, changing, or discontinuing any medication or supplement.